未名醫藥(002581.SZ)與加方協商擬解散合資公司未名西大
格隆匯11月29日丨未名醫藥(002581.SZ)公佈,北京未名西大生物科技有限公司(“未名西大”)系由公司全資子公司未名生物醫藥有限公司(“未名生物”)與加拿大西安大略大學(“加方”)於2013年6月3日合資成立,注冊資本人民幣1000萬元,其中未名生物佔股75%,加方佔股25%。
成立未名西大的初衷為推進兩項加方提供的基礎研究技術的研發以期實現產業化。由於加方提供的兩項技術屬於基礎研究早期成果,目前無法提供充分的技術資料以供未名西大重復其實驗並推進該項目的研發。今年年初,加方提出擬從合資公司撤資的請求。經諮詢相關政府部門,外方撤資合資公司可轉為內資企業或雙方協議解散合資公司。由於未名西大無法達到其合營目的,經評估,公司與加方協商擬解散合資公司,停止此兩項技術的合作。
2019年11月29日,公司第四屆董事會第六次會議審議通過《關於孫公司擬實施解散和清算的議案》。
由於未名西大成立以來沒有其他經營項目,研發項目也無進展,因此不會對公司持續經營能力造成影響,但對子公司財務報表合並範圍產生一定影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.